KROS

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Keros Therapeutics Inc

NASDAQ | KROS

15.52

USD

$0.00

(

0.00%

)

At Close (As of Nov 5, 2025)

$473.75M

Market Cap

48.59

P/E Ratio

0.32

EPS

$72.37

52 Week High

$9.11

52 Week Low

HEALTHCARE

Sector

KROS Chart

Recent Chart
Price Action

KROS Technicals

Tags:

KROS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.6M
Total Revenue $3.6M
Cost Of Revenue $1.2M
Costof Goods And Services Sold $1.2M
Operating Income -$211M
Selling General And Administrative $41M
Research And Development $174M
Operating Expenses $214M
Investment Income Net -
Net Interest Income $0
Interest Income -
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$187M
Income Tax Expense $300K
Interest And Debt Expense -
Net Income From Continuing Operations -$187M
Comprehensive Income Net Of Tax -
Ebit -$187M
Ebitda -$186M
Net Income -$187M

Revenue & Profitability

Earnings Performance

KROS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $616M
Total Current Assets $589M
Cash And Cash Equivalents At Carrying Value $560M
Cash And Short Term Investments $560M
Inventory -
Current Net Receivables $4.5M
Total Non Current Assets $27M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $25M
Other Non Current Assets -
Total Liabilities $44M
Total Current Liabilities $27M
Current Accounts Payable $4.6M
Deferred Revenue -
Current Debt -
Short Term Debt $2M
Total Non Current Liabilities $17M
Capital Lease Obligations $19M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $19M
Other Current Liabilities $21M
Other Non Current Liabilities -
Total Shareholder Equity $572M
Treasury Stock -
Retained Earnings -$569M
Common Stock $4K
Common Stock Shares Outstanding $37M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$161M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.2M
Capital Expenditures $1.9M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$1.9M
Cashflow From Financing $392M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$187M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.6M
Total Revenue $3.6M
Cost Of Revenue $1.2M
Costof Goods And Services Sold $1.2M
Operating Income -$211M
Selling General And Administrative $41M
Research And Development $174M
Operating Expenses $214M
Investment Income Net -
Net Interest Income $0
Interest Income -
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$187M
Income Tax Expense $300K
Interest And Debt Expense -
Net Income From Continuing Operations -$187M
Comprehensive Income Net Of Tax -
Ebit -$187M
Ebitda -$186M
Net Income -$187M

KROS News

KROS Profile

Keros Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts, dedicated to developing transformative therapies for hematological and musculoskeletal disorders. The company is advancing a proprietary pipeline of drug candidates designed to address significant unmet medical needs in these challenging therapeutic areas. With a strong focus on scientific innovation and comprehensive clinical development, Keros Therapeutics is strategically poised to enhance patient outcomes and expand treatment alternatives within the biopharmaceutical landscape.

NVVE
+17.61%
$0.24
MTC
+87.40%
$0.56
ASST
+15.20%
$1.44
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
RIVN
+24.05%
$15.50
GPUS
+12.96%
$0.39
LNAI
+37.88%
$1.14
PLUG
-8.36%
$2.52
NVDA
+1.26%
$201.21
CHR
+8.10%
$0.13
RUBI
-54.40%
$0.27
T
-0.36%
$24.44
SLDP
+53.69%
$8.63
F
-1.69%
$12.79
AXDX
-61.36%
$0.03
BYND
-1.87%
$1.30
PLTR
-2.34%
$186.26
ADAP
-15.14%
$0.05
WTO
-5.83%
$0.04
AAPL
+0.36%
$270.04
DNN
-2.91%
$2.66
BMNR
-7.93%
$39.46
PINS
-21.31%
$25.89
TSLA
+2.39%
$454.90
CIFR
+7.46%
$24.19
AMD
+2.62%
$256.61
YDKG
-3.51%
$0.05
NFE
+15.54%
$1.55
RXRX
-0.40%
$4.98
SMCI
-9.43%
$42.93
TEVA
+22.06%
$24.97
RMBL
+60.50%
$3.21
DVLT
-9.55%
$1.61
SOFI
+1.70%
$29.87
ADD
-25.47%
$0.05
BITF
+3.77%
$3.98
AAL
+5.91%
$13.39
INTC
+2.46%
$37.94
ETHD
-13.88%
$4.52
SRM
+53.27%
$10.30
SNAP
+0.06%
$7.47
ONDS
-0.75%
$5.91
EPWK
-7.88%
$0.06
BAC
-1.35%
$52.81
ZDAI
+18.33%
$0.54
QS
+12.56%
$17.37
NAKA
-11.88%
$0.78
KDLY
-11.88%
$0.78
KVUE
+2.09%
$16.30
GOOGL
-2.17%
$277.54
VALE
+3.05%
$12.30
FUBO
+7.33%
$3.95
APLD
-5.50%
$31.06
WLGS
-5.57%
$0.04
ACHR
-1.04%
$9.46
TLRY
+3.63%
$1.28
IREN
+9.70%
$73.09
NVO
-0.87%
$47.82
MARA
+3.29%
$17.16
BTG
+1.62%
$4.06
ETWO
0.00%
$3.30
APPS
+22.90%
$7.27
BBD
-1.15%
$3.41
RIG
+0.76%
$3.93
BURU
-3.24%
$0.28
ABEV
+1.70%
$2.39
RDHL
+15.74%
$1.25
WULF
-0.40%
$14.94
U
+11.87%
$40.13
CAN
+8.55%
$1.20
BTBT
+2.06%
$3.24
HTZ
-4.60%
$6.42
RGTI
+4.57%
$36.78
WBD
+1.77%
$23.00
NOK
+0.80%
$6.86
AFMD
-34.94%
$0.18
BW
+35.56%
$5.07
NIO
+2.65%
$7.35
NCLH
-0.43%
$18.70
RIOT
-3.78%
$18.54
QBTS
+4.05%
$30.94
HIMS
+5.35%
$45.08
AG
-7.43%
$10.70
AMZN
+0.05%
$249.46
NVTS
-7.60%
$9.66
PCG
+1.39%
$16.38
CMBM
-7.05%
$3.01
MSPR
-24.83%
$0.49
GRAB
-0.60%
$5.75
KLG
-9.05%
$13.35
JOBY
+3.05%
$15.21
CLOV
-16.19%
$2.95
ALIT
-9.28%
$2.44
XAIR
-5.43%
$1.75
GRYP
-10.38%
$1.38
KHC
-0.65%
$24.17
ORIS
-20.21%
$0.12
PLTD
+1.50%
$6.44
FITB
+1.49%
$42.15
NVVE
+17.61%
$0.24
MTC
+87.40%
$0.56
ASST
+15.20%
$1.44
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
RIVN
+24.05%
$15.50
GPUS
+12.96%
$0.39
LNAI
+37.88%
$1.14
PLUG
-8.36%
$2.52
NVDA
+1.26%
$201.21
CHR
+8.10%
$0.13
RUBI
-54.40%
$0.27
T
-0.36%
$24.44
SLDP
+53.69%
$8.63
F
-1.69%
$12.79
AXDX
-61.36%
$0.03
BYND
-1.87%
$1.30
PLTR
-2.34%
$186.26
ADAP
-15.14%
$0.05
WTO
-5.83%
$0.04
AAPL
+0.36%
$270.04
DNN
-2.91%
$2.66
BMNR
-7.93%
$39.46
PINS
-21.31%
$25.89
TSLA
+2.39%
$454.90
CIFR
+7.46%
$24.19
AMD
+2.62%
$256.61
YDKG
-3.51%
$0.05
NFE
+15.54%
$1.55
RXRX
-0.40%
$4.98
SMCI
-9.43%
$42.93
TEVA
+22.06%
$24.97
RMBL
+60.50%
$3.21
DVLT
-9.55%
$1.61
SOFI
+1.70%
$29.87
ADD
-25.47%
$0.05
BITF
+3.77%
$3.98
AAL
+5.91%
$13.39
INTC
+2.46%
$37.94
ETHD
-13.88%
$4.52
SRM
+53.27%
$10.30
SNAP
+0.06%
$7.47
ONDS
-0.75%
$5.91
EPWK
-7.88%
$0.06
BAC
-1.35%
$52.81
ZDAI
+18.33%
$0.54
QS
+12.56%
$17.37
NAKA
-11.88%
$0.78
KDLY
-11.88%
$0.78
KVUE
+2.09%
$16.30
GOOGL
-2.17%
$277.54
VALE
+3.05%
$12.30
FUBO
+7.33%
$3.95
APLD
-5.50%
$31.06
WLGS
-5.57%
$0.04
ACHR
-1.04%
$9.46
TLRY
+3.63%
$1.28
IREN
+9.70%
$73.09
NVO
-0.87%
$47.82
MARA
+3.29%
$17.16
BTG
+1.62%
$4.06
ETWO
0.00%
$3.30
APPS
+22.90%
$7.27
BBD
-1.15%
$3.41
RIG
+0.76%
$3.93
BURU
-3.24%
$0.28
ABEV
+1.70%
$2.39
RDHL
+15.74%
$1.25
WULF
-0.40%
$14.94
U
+11.87%
$40.13
CAN
+8.55%
$1.20
BTBT
+2.06%
$3.24
HTZ
-4.60%
$6.42
RGTI
+4.57%
$36.78
WBD
+1.77%
$23.00
NOK
+0.80%
$6.86
AFMD
-34.94%
$0.18
BW
+35.56%
$5.07
NIO
+2.65%
$7.35
NCLH
-0.43%
$18.70
RIOT
-3.78%
$18.54
QBTS
+4.05%
$30.94
HIMS
+5.35%
$45.08
AG
-7.43%
$10.70
AMZN
+0.05%
$249.46
NVTS
-7.60%
$9.66
PCG
+1.39%
$16.38
CMBM
-7.05%
$3.01
MSPR
-24.83%
$0.49
GRAB
-0.60%
$5.75
KLG
-9.05%
$13.35
JOBY
+3.05%
$15.21
CLOV
-16.19%
$2.95
ALIT
-9.28%
$2.44
XAIR
-5.43%
$1.75
GRYP
-10.38%
$1.38
KHC
-0.65%
$24.17
ORIS
-20.21%
$0.12
PLTD
+1.50%
$6.44
FITB
+1.49%
$42.15
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.